Equity Profile

FOLD

Amicus Therapeutics, Inc.

Health CareBiotechnology$4.5B

May4Mon

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

$-0.08

Revenue

Revenue growth is critical for assessing the company's market performance and demand for its products.

$160M

Wall Street expectations, options signals, track record, and call prep available with Pro.

FOLD Q1-2026 Earnings Preview

Context

Company Snapshot

Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options for patients with unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+157.80%

Avg Stock Reaction

-1.80%

Last Quarter Recap

In Q4-2025, Amicus reported an EPS of $0.10, exceeding expectations by 49.25%. However, the stock experienced a slight decline the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continue to advance pipeline programs aimed at rare diseases.
Focus on expanding market access for existing therapies.
Enhance operational efficiency to improve financial performance.

Expectations

Wall Street Expectations

Analysts expect Amicus to report a loss this quarter, but with a revenue forecast suggesting steady demand for its products. The market is watching closely for any signs of growth or operational improvements.

Bull Case

If Amicus beats EPS and revenue expectations, it could signal strong demand for its therapies and effective cost management, leading to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and ability to sustain operations, potentially leading to a significant stock drop.

Key Metrics to Watch

EPS

$-0.08

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

Revenue

$160M

Revenue growth is critical for assessing the company's market performance and demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide clarity on revenue growth trends for its key therapies?

Understanding revenue trends is crucial for assessing the company's market position and future growth potential.

What specific cost management strategies will Amicus implement to improve EPS?

Effective cost management can significantly impact profitability and investor confidence, especially in a loss-making scenario.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches, which could significantly boost earnings this quarter.

Supporting Evidence

The company's recent successes in clinical trials may not be fully reflected in current revenue estimates.

Options pricing suggests a lower expected move compared to historical averages, indicating potential undervaluation of the stock's volatility.

Key Risk

If revenue exceeds $166M, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely scrutinized, especially in light of previous earnings surprises and the need for consistent growth.

Bull Confirmed If

Achieving revenue of $166M or higher would confirm strong demand for Amicus's therapies.

Bear Confirmed If

Revenue falling below $149M would raise concerns about market demand and operational execution.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±5.5%

Pricing cheap

The options market is pricing in a modest move around earnings, suggesting that investors are uncertain about significant changes in the stock price.

Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.7%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amicus beats expectations, history suggests a potential average one-day move of +1.13%, confirming a positive outlook.

In-Line / Cautious

An in-line report could lead to muted reactions as investors await further guidance, reflecting the mixed sentiment seen in past quarters.

Miss

If the company misses expectations, history suggests an average one-day move of -6.51%, likely leading to increased selling pressure.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of key therapies and any new product launches.
2Updates on cost management initiatives and their expected impact on profitability.
3Any changes in market access strategies that could affect revenue.
4Insights into upcoming clinical trials and their potential implications for future growth.
5Management's outlook on the competitive landscape and how it may influence Amicus's market position.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

$-0.08

Revenue

Revenue growth is critical for assessing the company's market performance and demand for its products.

$160M

Wall Street expectations, options signals, track record, and call prep available with Pro.

FOLD Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+157.80%

Avg Stock Reaction

-1.80%

Last Quarter Recap

In Q4-2025, Amicus reported an EPS of $0.10, exceeding expectations by 49.25%. However, the stock experienced a slight decline the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continue to advance pipeline programs aimed at rare diseases.
Focus on expanding market access for existing therapies.
Enhance operational efficiency to improve financial performance.

Expectations

Wall Street Expectations

Bull Case

If Amicus beats EPS and revenue expectations, it could signal strong demand for its therapies and effective cost management, leading to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and ability to sustain operations, potentially leading to a significant stock drop.

Key Metrics to Watch

EPS

$-0.08

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

Revenue

$160M

Revenue growth is critical for assessing the company's market performance and demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide clarity on revenue growth trends for its key therapies?

Understanding revenue trends is crucial for assessing the company's market position and future growth potential.

What specific cost management strategies will Amicus implement to improve EPS?

Effective cost management can significantly impact profitability and investor confidence, especially in a loss-making scenario.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches, which could significantly boost earnings this quarter.

Supporting Evidence

The company's recent successes in clinical trials may not be fully reflected in current revenue estimates.

Options pricing suggests a lower expected move compared to historical averages, indicating potential undervaluation of the stock's volatility.

Key Risk

If revenue exceeds $166M, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely scrutinized, especially in light of previous earnings surprises and the need for consistent growth.

Bull Confirmed If

Achieving revenue of $166M or higher would confirm strong demand for Amicus's therapies.

Bear Confirmed If

Revenue falling below $149M would raise concerns about market demand and operational execution.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±5.5%

Pricing cheap

The options market is pricing in a modest move around earnings, suggesting that investors are uncertain about significant changes in the stock price.

Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.7%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amicus beats expectations, history suggests a potential average one-day move of +1.13%, confirming a positive outlook.

In-Line / Cautious

An in-line report could lead to muted reactions as investors await further guidance, reflecting the mixed sentiment seen in past quarters.

Miss

If the company misses expectations, history suggests an average one-day move of -6.51%, likely leading to increased selling pressure.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of key therapies and any new product launches.
2Updates on cost management initiatives and their expected impact on profitability.
3Any changes in market access strategies that could affect revenue.
4Insights into upcoming clinical trials and their potential implications for future growth.
5Management's outlook on the competitive landscape and how it may influence Amicus's market position.